Tiopronin
Tiopronin (alpha-mercaptopropionylglycine) is a free thiol compound that forms mixed disulfide bonds with cysteine in urine, producing a more soluble cysteine-tiopronin complex that prevents cystine stone formation in patients with cystinuria by reducing free urinary cystine concentration below its saturation threshold. It is also used for the treatment of Wilson's disease as a copper-chelating agent and as a disease-modifying agent in rheumatoid arthritis. Its thiol group provides the chemical reactivity underlying all its clinical applications.
分子量
163.2000 g/mol
LogP
-0.10
TPSA
67.40 Ų
リピンスキーの五則
適合
作用機序
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.
2D構造
Cite this structure
Embed this structure
SMILES
CC(S)C(=O)NCC(=O)O
InChI
InChI=1S/C5H9NO3S/c1-3(10)5(9)6-2-4(7)8/h3,10H,2H2,1H3,(H,6,9)(H,7,8)
Molecular Formula
C5H9NO3S
HBD / HBA
3 / 4
回転可能結合数
3
重原子数
10
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Tiopronin (alpha-mercaptopropionylglycine) is a free thiol compound that forms mixed disulfide bonds with cysteine in urine, producing a more soluble cysteine-tiopronin complex that prevents cystine stone formation in patients with cystinuria by reducing free urinary cystine concentration below its saturation threshold. It is also used for the treatment of Wilson's disease as a copper-chelating agent and as a disease-modifying agent in rheumatoid arthritis. Its thiol group provides the chemical reactivity underlying all its clinical applications.
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.
Yes, Tiopronin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1314. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5483. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tiopronin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tiopronin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tiopronin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tiopronin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tiopronin"></drugfyi-drug>